Urinary beta-glucuronidase in renal cell carcinoma

Area of Science:

• Biochemistry
• Urology
• Oncology

Background:

• Renal cell carcinoma (RCC) is a significant health concern.
• Accurate diagnostic markers for RCC are crucial for early detection and treatment.
• Urinary enzyme activity can reflect renal pathology.

Purpose of the Study:

• To investigate urinary beta-glucuronidase activity in patients with histopathologically confirmed RCC.
• To compare enzyme levels between RCC patients and healthy controls.
• To assess the correlation of enzyme activity with tumor stage and urinary sediment findings.

Main Methods:

• Collected urine samples from 30 RCC patients and 32 healthy controls.
• Measured urinary beta-glucuronidase activity.
• Classified RCC patients using the TNM staging system.
• Analyzed urinary sediment for hematuria, pyuria, and bacteriuria.

Main Results:

• A statistically significant increase (p < 0.01) in urinary beta-glucuronidase activity was observed in RCC patients.
• The elevated enzyme activity was independent of urinary sediment abnormalities.
• No correlation was found between enzyme levels and tumor dissemination (TNM staging).

Conclusions:

• Urinary beta-glucuronidase activity is a potential biomarker for diagnosing malignant renal tumors.
• Elevated levels suggest a role in RCC pathogenesis or as an indicator of malignancy.
• Further research is warranted to validate its clinical utility in RCC diagnosis.